
VisEn Medical
VisEn Medical, Inc designs, develops, and commercializes fluorescence in vivo imaging technology platforms The company’s Fluorescence.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | N/A | Acquisition | |
Total Funding | 000k |
Related Content
VisEn Medical, Inc. was a specialized developer of in vivo fluorescence imaging platforms, founded in 2000 by Ralph Weissleder, MD, PhD, and Kirtland Poss. The company's technology originated from research conducted at the Center for Molecular Imaging Research at Massachusetts General Hospital. Dr. Weissleder, a clinician-scientist and professor at Harvard Medical School, brought extensive expertise in molecular imaging, nanotechnology, and systems biology to the venture. His research has consistently focused on developing novel technologies for early disease detection, particularly in cancer and inflammation, which formed the scientific bedrock of VisEn.
The company's core business centered on providing advanced tools for preclinical research. Its product line included Fluorescence Molecular Tomographic (FMT™) imaging systems and a portfolio of proprietary fluorescence imaging agents. These systems enabled researchers to quantitatively visualize and measure a range of biological processes and disease biomarkers deep within living organisms, a significant step in understanding disease progression and the efficacy of potential therapies. The technology was designed to bridge the gap between in vitro cellular studies and in vivo biological activity, offering a clearer path toward understanding human responses to new drugs.
VisEn served a distinct client base that included academic research institutions, pharmaceutical companies, and contract research organizations (CROs). The company generated revenue through the sale of its imaging systems and reagents, such as ProSense®, IntegriSense™, and OsteoSense®. It also collaborated with pharmaceutical partners to create custom molecular imaging agents for specific research needs. In August 2010, PerkinElmer, Inc. acquired VisEn Medical to expand its own cellular imaging business and capabilities in the preclinical research market. The acquisition integrated VisEn's in vivo imaging technologies into PerkinElmer's broader suite of tools for the life sciences and drug discovery pipeline.
Keywords: VisEn Medical, in vivo imaging, molecular imaging, fluorescence molecular tomography, preclinical research, Ralph Weissleder, PerkinElmer, disease biomarkers, drug discovery tools, cellular imaging, FMT imaging systems, fluorescence agents, cancer research, inflammation research, cardiovascular research, translational research, life sciences technology, Kirtland Poss, Massachusetts General Hospital, optical imaging